E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, ...

Previous studies on the value of brain natriuretic peptide in diastolic dysfunction have been largely limited to male subjects. The authors found that female gender, in addition to diastolic ...

Circulating concentrations of B-type natriuretic peptide (BNP) and the N-terminal fragment (NT) of its prohormone (proBNP) are related to cardiac function and have emerged as clinically useful ...

Obesity influences the thresholds, but even in nonobese patients with dyspnea, optimal cutoffs may be lower than recommended.

B-type natriuretic peptide is released by cardiac myocytes in response to wall stretch. There are many hemodynamic effects of BNP which are beneficial in the setting of decompensated congestive ...

Atrial natriuretic peptide (ANP) is similar to b-type natriuretic peptide (BNP) in the hemodynamic effects. ANP is not measured clinically unlike BNP. It is released in response to myocyte stretch ...

The N-terminal pro–B-type natriuretic peptide (NT-proBNP) level is 1529 pg per milliliter. Echocardiography reveals left ventricular dimensions within the normal range, left ventricular ...

Past research has shown how native C-type natriuretic peptide (CNP), a 22-amino acid peptide produced by endothelial cells ...

The inactive N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) has been linked to ventricular dysfunction in the general population, and is predictive of cardiac events. Corteville ...

Achondroplasia, which affects around one in 20,000 babies, has just one approved treatment: BioMarin’s Voxzogo. However, new ...

The chambers release peptide hormones, including ‘atrial natriuretic peptide’ and ‘brain natriuretic peptide’, which help regulate the balance of fluid in the body by affecting the kidneys.